A ‘Leap’ Toward Humanity’s Destruction

This article primarily appeared on Unlimited Hangout.

The world’s richest medical investigate footing, the Wellcome Trust, has teamed up with a pair of onetime DARPA leads who improved Silicon Valley’s skunkworks to usher in an age of nightmarish surveillance, including for children older and younger as 3 month age-old. Their agenda can only advance if we allow it.

A UK nonprofit with ties to world-wide decay throughout the COVID-1 9 crisis as well as historical and current ties to the UK eugenics action launched a global health-focused DARPA equivalent last year. The move travelled largely unnoticed by both mainstream and independent media.

The Wellcome Trust, which has arguably been second only to Bill Gates in its ability to influence contests during the COVID-1 9 crisis and vaccination campaign, launched its own world-wide equivalent of the Pentagon's reticent investigate agency last year, officially to combat the "most pressing health challenges of our time."

Though first envisioned of in 2018, this particular Wellcome Trust initiative was spun off from the Trust last-place May with $300 million in initial fund. It promptly captivated two onetime DARPA executives, who had previously served in the upper echelons of Silicon Valley, to manage and plan its portfolio of projects.

This world-wide health DARPA, known as Wellcome Leap, seeks to achieve "breakthrough scientific and technological solutions" by or before 2030, with a focus on "complex world health challenges." The Wellcome Trust is open about how Wellcome Leap will apply the approaches of Silicon Valley and venture capital firms to the health and life science sector.

Unsurprisingly, their three current programs are poised to develop incredibly invasive tech-focused, and in a number of cases overtly transhumanist, medical engineerings, including a program alone focused on using artificial intelligence( AI ), portable sensors, and wearable brain-mapping tech "for childrens" 3 years old and younger.

This Unlimited Hangout investigation explores not only the four current programs of Wellcome Leap but likewise the person or persons behind it. The arising representation is of an fantastically malevolent assignment that poses not only a great threat to current culture but to the future of humanity itself. An upcoming Unlimited Hangout investigation will examine the history of the Wellcome Trust along with its role in recent and current events.

Leap's Leadership: Merging Man and Machine for the Military and Silicon Valley

The intentions of the Wellcome Leap are made clear by the woman chosen to lead it, onetime chairman of the Pentagon's DARPA, Regina Dugan. Dugan began her occupation at DARPA in 1996; she passed a counterterrorism task force in 1999 before leaving DARPA about a year later.

After departing DARPA, she cofounded her own venture capital firm, Dugan Ventures, and then became special adviser to the US Army's vice chief of staff from 2001 to 2003, which coincides with the attacks of Afghanistan and Iraq. In 2005, she developed a defense-focused tech conglomerate announced RedXDefense, which contracts with the military and specifically for DARPA.

In 2009, under the Obama administration, Dugan was appointed director of DARPA by Defense Secretary Robert Gates. Much was compiled over her being the first girl chairman of relevant agencies, but she is best remembered at relevant agencies for her so-called "Special Forces" approach to invention. During her term, she created DARPA's now defunct Transformational Convergence Technology Office, which focused on social networks, synthetic biology, and machine intelligence.

Many of the topics previously to be organized by that bureau are now overseen by DARPA's Biological Technology Office, which was created in 2014 and focuses on everything "from programmable microbes to human-machine symbiosis." The Biological Technologies Office, like Wellcome Leap, engages a mixture of "health-focused" biotechnology programs and transhumanist endeavors.

Right before leaving the top capacity at DARPA, Dugan greenlighted the agency's initial investments in mRNA vaccine technology, which led to DARPA's investments in Pfizer and Moderna shortly after. The DARPA scientist who lobbied Dugan to back the program, Dan Wattendorf , now labor as the director of Innovative Technology Solutions at the Bill& Melinda Gates Foundation.

While Dugan's efforts at DARPA are recollected lovingly by those in the national-security state, and also by those working in Silicon Valley, Dugan was investigated for conflicts of interest during her experience as DARPA's director, as her conglomerate RedXDefense acquired millions in Department of Defense contracts during her tenure.

Though she had recused herself from any formal role at the company while heading DARPA, she continued to hold a significant financial stake in the company, and a military investigation later discovered she had infringed moralities rules to a significant degree.

Instead of being held accountable in any way, Dugan went on to become a top executive at Google, where she was brought on to manage Google's Advanced Technology and Product Group( ATAP ), which it had spun out of Motorola Mobility after Google's acquisition of that company in 2012. Google's ATAP was modeled after DARPA and filled other ex-DARPA officials besides Dugan.

At Google, Dugan oversaw various programmes, including what is now the basis of Google's "augmented reality" business, then known as Project Tango, as well as "smart" clothing in which multitouch sensors were knitted into textiles. Another projection that Dugan produced involved the purpose of applying a "digital tattoo" to unlock smartphones. Perhaps most controversially, Dugan was also behind the process of drafting a "digital authentication pill."

According to Dugan, when the pill is immersed, "your entire body becomes your authentication token." Dugan made the pill and many of her other efforts at Google as working to fix "the mechanical mismatch between humans and electronics" by making engineering that mixes the human body with machines to going degrees.

While serving in this capacity at Google, Dugan chaired a committee at the 2013 Clinton Global Initiative called "Game-Changers in Technology" and attended the 2015 Bilderberg meeting where AI was a primary topic of discussion.

In 2016, Dugan left Google for Facebook where she was chosen to be the first head of Facebook's own DARP-Aequivalent research agency, then known as Building 8. DARPA's ties to the beginnings of Facebook were discussed in a recent Unlimited Hangout report.

Under Dugan, Building 8 invested heavily in brain-machine interface technology, which has since produced the company's "neural wearable" wristbands that claim to be able to anticipate movements of the handwriting and digits from mentality signals alone. Facebook showcased prototypes of the project earlier this year.

Dugan left Facebook precisely eighteen months after joining Building 8, announcing her projects "to focus on building and contributing a brand-new endeavor, " which was apparently a have referred to Wellcome Leap. Dugan later said it was as if she had been training courses for her persona at Wellcome Leap ever since participate the workforce, making it as the spire of her career.

When invited in an interview earlier this year who the customer of Wellcome Leap are, Dugan dedicated a long-winded answer but basically responded that the project suffices the biotech and pharmaceutical industries, international organizations such as the UN, and public-private partnerships.

In addition to her persona at Wellcome, Dugan is also a member of the Council on Foreign Relations-sponsored taskforce on US Technology and Innovation policy, which was formed in 2019. Other members include LinkedIn's Reid Hoffman, McKinsey Institute Global Chairman James Manyika, onetime head of Google Eric Schmidt and President Biden's controversial top discipline consultant Eric Lander.

The other exec at Wellcome Leap, chief operating officer Ken Gabriel, has a background closely tied to Dugan's. Gabriel, like Dugan, is a former planned manager at DARPA, where he produced the agency's microelectromechanical organizations( MEMS) investigate from 1992 to 1996.

He served as deputy managing director of DARPA from 1995 to 1996 and became head of the Electronics Technology Office from 1996 to 1997, where he was reportedly responsible for about half of all federal electronics-technology assets. At DARPA, Gabriel worked closely with the FBI and the CIA.

Ken Gabriel- COO of Wellcome Leap. Source: Wellcome Leap

Gabriel left DARPA for Carnegie Mellon University, where he was in charge of the Office for Security Technologies in the aftermath of September 11, 2001. That power was created after 9/11 precisely to help meet the national-security needs of the federal government departments, according to Carnegie Mellon's announcement of the program.

Around that same time, Gabriel became regarded as "the architect of the MEMS industry" due to his past work at DARPA and his founding of the MEMS-focused semiconductor company Akustica in 2002. He acted as Akustica's chairman and chief technology officer until 2009, at which epoch he returned to work at DARPA where he dished as the agency's deputy director, running instantly under Regina Dugan.

In 2012, Gabriel followed Dugan to Google's Advanced Technology and Product Group, which he was actually responsible for creating. According to Gabriel, Google cofounders Larry Page and Sergey Brin assignment Gabriel with creating "a private sector ground-up model of DARPA" out of Motorola Mobility. Regina Dugan was placed in charge, and Gabriel again performed as her deputy.

In 2013, Dugan and Gabriel co-wrote a piece for the Harvard Business Review about how DARPA's "Special Forces" innovation approach could revolutionize both both the public and private sectors if more widely applied.

Gabriel left Google in 2014, well before Dugan, to serve as the president and CEO of Charles Stark Draper Laboratories, better known as Draper Labs, which develops "innovative technology solutions" for the national-security community, with a focus on biomedical organisations, vitality, and space technology. Gabriel held that position until he abruptly resigned in 2020 to co-lead Wellcome Leap with Dugan.

In addition to his persona at Wellcome, Gabriel is also a World Economic Forum "technology pioneer" and on the board of directors of Galvani Bioelectronics, a seam venture of GlaxoSmithKline, which is intimately linked to the Wellcome Trust, and the Google affiliate Verily.

Galvani focuses on the development of "bioelectronic medicines" that are related to "implant-based modulation of neural signals" in an overt move by the pharmaceutical industry and Silicon Valley to normalize transhumanist "medicines."

The longtime chairman of the board of Galvani, on which Gabriel dishes, was Moncef Slaoui, who led the US COVID-1 9 inoculation growth and dissemination program Action Warp Speed. Slaoui was relieved of its own position at Galvani this past March over well-substantiated claims of sexual harassment.

Jeremy Farrar, Pandemic Narrative Manager

While Dugan and Gabriel ostensibly guide the organization, Wellcome Leap is the brainchild of Jeremy Farrar and Mike Ferguson, who serve as its leads. Farrar is the director of the Wellcome Trust itself, and Ferguson is agent chair of the Trust's board of governors.

Farrar has been lead of the Wellcome Trust since 2013 and has participates actively in critical decision making at the highest level globally since the beginning of the COVID crisis. He is too an agenda contributor to the World Economic Forum and cochaired the WEF's Africa meeting in 2019.

Farrar's Wellcome Trust is also a WEF strategic partner and cofounded the COVID Action Platform with the WEF. Farrar was more recently behind the creation of Wellcome's COVID-Zero initiative, which is also bind to the WEF.

Farrar has formulated its own initiative as "an opportunity for companies to advance the science which will eventually reduce business disruption." Thus far it has persuaded titans of finance, including Mastercard and Citadel, to invest millions in research and development at makings favored by the Wellcome Trust.

Wellcome Trust Director Jeremy Farrar with NTI Co-Chairman Sam Nunn, who led the 2001 Dark Winter exercise.

Source: NTI.com

Some of Wellcome's controversial medical-research projects in Africa, as well as its ties to the UK eugenics advance, were investigated in a December article published at Unlimited Hangout.

That report too explores the intimate alliances of Wellcome to the Oxford-AstraZeneca COVID-1 9 vaccine, the purpose of applying which has now been restricted or banned in several countries. As mentioned in the introduction, the Wellcome Trust itself is the victim of an upcoming Unlimited Hangout investigation( Place 2 ).

Jeremy Farrar, who was born in Singapore in 1961, had previously been conductor of the Oxford University Clinical Research Unit in Ho Chi Minh City, beginning in 1998. During that time, he authored innumerable epidemiological research papers. He claimed in a 2014 Financial Times article that his decision to move to Vietnam was due to his indifference for discussion auditoriums full of lily-white men.

Southeast Asia was obviously a much less adjusted environment for someone in the medical-research industry wishing to indulge in groundbreaking research. Although based in Vietnam, Farrar was sent by Oxford to many locations around the globe to study epidemics happening in real time.

In 2009, when swine influenza was creating disruption in Mexico, Farrar jumped on an aeroplane to dive right into the action, something he too did for subsequent world-wide outbreaks of Ebola, MERS, and avian flu.

Over the past year, many questions have arisen regarding exactly how much power Farrar exercises over world public health policy. Recently, the US president's chief medical adviser, Anthony Fauci, was forced to release his emails and match from March and April 2020 at the request of the Washington Post.

The released emails disclose what appears to be a high-level conspiracy by some of the top medical officials in the US to falsely claim that COVID-1 9 could only have been of zoonotic parentage, despite clues to the contrary. The emails were heavily redacted as such emails frequently are, supposedly to protect the information of the people involved, but the "( b )( 6) " redactions also protect much of Jeremy Farrar's input into these discussions.

Chris Martenson, financial researcher and post-doctorate student of neurotoxicology and founder of Peak Prosperity, has had some insightful observations on the matter, including asking why this protection has been offered to Farrar given that he is the director of a "charitable trust." Martenson went on to question why the Wellcome Trust was involved at all in these high-level discussions.

One Fauci email, dated February 25, 2020, and sent by Amelie Rioux of the WHO, stated that Jeremy Farrar's official persona at that time was "to act as the board's focal point on the COVID-1 9 outbreak, to represent and advise the board on the science of the eruption and the financing of the response."

Farrar had previously chaired the WHO's Scientific Advisory Council. The emails likewise prove the prep, within a ten-day period, of the SARS-CoV-2 "'origins" paper, which was entitled "The Proximal Origin of SARS-CoV-2" and was accepted for booklet by Nature Medicine on March 17, 2020.

The paper claimed that the SARS-CoV-2 virus could only have come from natural causes as opposed to gain-of-function research, a claim formerly deemed as truth in the mainstream but which is coming back under appreciable inquiry in recent weeks.

Shaping the presentation of an beginning floor for a virus of global relevance is something Farrar has been involved with before. In 2004-5, it was reported that Farrar and his Vietnamese colleague Tran Tinh Hien, the weaknes lead at the Hospital for Tropical Infection, were the first to identify the re-emergence of the avian influenza( H5N1) in humans.

Farrar has portrayed the start tale on many occasions, territory: "It was a boy. She caught it from a pet duck that just died and she'd dug up and reburied. She survived." Harmonizing to Farrar, its own experience prompted him to found a global network in conjunction with the World Health Organization to "improve regional responses to disease outbreaks."

An article published by Rockefeller University Press's Journal of Experimental Medicine in 2009 is dramatically named, "Jeremy Farrar: When Disaster Strikes." Farrar, when referring to the H5N 1 parentage narration stated: "The WHO people--and this is not a criticism--decided it was unlikely that the child had SARS or avian influenza.

They left, but Professor Hien abode behind to talk with the child and her mum. The girlfriend admitted that she had been quite sad in the previous days with the death of her baby duck. The daughter and her brother had pushed over burying the duck and, because of this argument, she had gone back, excavate up the duck, and reburied it--probably so her friend wouldn't know where it was buried.

With that biography, Professor Hien phoned me at home and said he was worried about the child. He made some swabs from the child's nose and throat and bring them back to the hospital. That night the laboratory ranged research on the samples, and they were positive for Influenza A."

With Farrar now having been uncovered as an instrumental part of the team that crafted the official story regarding the parentages of SARS-CoV-2, his previous assertions about the root of past outbreaks should be scrutinized.

As the director of a "charitable trust, " Jeremy Farrar is almost completely inexplicable for his involvement in crafting contentious narratives related to the COVID crisis. He continues to be at the forefront of the world-wide response to COVID, in part by launching the Wellcome Leap Fund for "unconventional programmes, funded at scale" as an overt attempt to create a global and "charitable" version of DARPA.

Indeed, Farrar, in conceiving Wellcome Leap, has arranged himself to be just as, if not more, instrumental in build the foundation for the post-COVID era as he was in building the foundation for the COVID crisis itself.

This is significant as Wellcome Leap CEO Regina Dugan has labeled COVID-1 9 this generation's "Sputnik moment" that will launch a new age of "health innovation, " much like the launching of Sputnik started a global technological "space age." Wellcome Leap fully intends to lead the pack.

"Rulers" of the Gene-Sequencing Industry

In contrast to the overt DARPA, Silicon Valley, and Wellcome ties-in of the others, the chairman of the board of directors of Wellcome Leap, Jay Flatley, has a different background. Flatley is the long-time head of Illumina, a California-based gene-sequencing hardware and software beings that is believed to currently predominate the field of genomics.

Though he stepped down from the board of Illumina in 2016, he has continued to serve as the executive chairman of its board of directors. Flatley was the first to be chosen for a lead statu at Wellcome Leap, and he was responsible for suggesting Regina Dugan for the organization's chief executive officer, according to a recent interrogation given by Dugan.

Illumina Campus. Source: Glassdoor

As a profile on Illumina in the business magazine Fast Company records, Illumina "operates behind the scenes, selling hardware and services to companies and research prisons, " among them 23 andMe. 23 andMe's CEO, Anne Wojcicki, the sister of YouTube CEO Susan Wojcicki and the spouse of Google cofounder Sergey Brin, told Fast Company, "It's crazy. Illumina is like the ruler of this whole universe and no one knows that."

The report aware of the fact that 23 andMe, like most business that furnish DNA sequencing and analysis to purchasers, utilizations machines produced by Illumina.

In 2016, Illumina propelled an "aggressive" five-year plan to "bring genomics out of research labs and into doctors' offices." Given the current state of things, peculiarly the global pushing toward gene-focused vaccines and rehabilitations, that programme, which concludes this year, could not have been any better timed.

Illumina's current CEO, Francis DeSouza, previously held key posts at Microsoft and Symantec. Also in 2016, Illumina's executive squads calculate a future in which humans are gene measured from birth to grave for both health and commercial purposes.

Whereas most companies have contended financially during the coronavirus pandemic, some have pictured a big an increasing number of profits. Illumina has witnessed its share price double since the start of the COVID crisis.

The company's$ 1 billion plus in revenues during the last tax year was obviously helped by the quick approval of the NovaSEQ 6000 machines, which can test a large number of COVID tests more quickly than other manoeuvres. An man machine has a hefty price tag of roughly$ 1 million, and thus they are mostly found at elite equipment, private labs, and top-tier universities.

Jay Flatley, Executive Chairman, Illumina, speaking at World Economic Forum in Davos 2018. Source: WEF

In addition to his long-standing leader character at Illumina, Jay Flatley is also a "digital member" of the World Economic Forum as well as the lead independent director of Zymergen, a WEF "tech pioneer" company that is "rethinking biology and reimagining the world."

Flatley, who has also attended several Davos satisfies, has addressed the WEF on the "promise of precision[ i.e ., gene-specific] medicine."

At another WEF panel meeting, Flatley, alongside UK Health Secretary Matt Hancock, promoted the relevant recommendations of building genomic sequencing of newborns at birth the norm, claiming it had "the potential to change the healthcare system from reactive to preventative."

Some at the panel called for the genomic sequencing of babies to eventually become mandatory.

Aside from Flatley as private individuals, Illumina as a company is a WEF partner and plays a key role in its pulpit regarding the future of health care. A top Illumina executive also acts on the WEF's Global Future Council on Biotechnology.

A New HOPE

Wellcome Leap currently has four curricula: Multi-Stage Psych, Delta Tissue, 1KD, and HOPE. HOPE was the first program to be announced by Wellcome Leap and stands for Human Organs, Physiology and Engineering. According to the full program description, HOPE strives "to leverage the supremacy of bioengineering to advance stem cells, organoids, and entire part the mechanisms and ties-in that recapitulate human physiology in vitro and regenerate vital gatherings in vivo."

Source: Wellcome Leap, https :// wellcomeleap.org/ hope /

HOPE consists of two main program destinations. First, it seeks to "bioengineer a multiorgan platform that recreates human immunological responses with sufficient faithfulnes to doubled the predictive appreciate of a preclinical tribulation with respect to efficacy, toxicity and immunogenicity for therapeutic interventions."

In other names, this bioengineered programme mimicking human organs would be used to test the effects of pharmaceutical products, including vaccines, which could create a situation in which animal inquiries shall be substituted for ordeals on gene-edited and raised organs.

Though such an advance would certainly be helpful in the sense of reducing often unethical animal experimentation, trusting such a novel organization to allow medical treatments to go straight to the human-testing phase would also require trusting the institutions developing that system and its funders.

As it stands now, the Wellcome Trust has too many ties to distort actors in the pharmaceutical industry, having initially begun as the "philanthropic" arm of UK drug giant GlaxoSmithKline, for anyone to trust what they are producing without actual independent affirmation, given the histories of some of their partners in fudging both animal and human clinical test data for inoculations and other products.

The second destination of HOPE is to open up the use of machine-human hybrid organs for transplantation into human being. That objective focuses on restoring "organ performs employing grown organs or biological/ synthetic composite systems" with the later goal of bioengineering a fully transplantable human organ after several years.

Later on in the program description, nonetheless, the interest in merging the synthetic and biological becomes clearer when it districts: "The hour is right to foster synergies between organoids, bioengineering and immunoengineering technologies, and breakthrough the state-of-the-art of in vitro human biology ... by building controllable, accessible and scalable systems."

The program description document also notes the interest of Wellcome in genetic-engineering approaches for the "enhancement of wanted owneds and insertion of traceable markers" and Wellcome's ambition to reproduce the building blocks of the human immune system and human organ arrangements through technological means.

Transhumanist Toddlers?

The second program to be pursued by Wellcome Leap is called "The First 1000 Epoches: Promoting Healthy Brain Networks, " which is abbreviated as 1KD by the organization. It is arguably the most unsettling program because it seeks to use young children, specifically infants from three months to three-year-old toddlers, as its test subjects.

The program is being overseen by Holly Baines, who previously acted as programme developing produce for the Wellcome Trust before assembling Wellcome Leap as the 1KD platform leader.

Source: Wellcome Leap, https :// wellcomeleap.org/ 1kd /

1KD is focused on developing "objective, scalable ways to assess a child's cognitive health" by monitoring the brain development and serve of infants and toddlers, countenancing practitioners to "risk-stratify children" and "predict responses to interventions" for the development of brains.

The program description document notes that, up to this point in biography, "our primary opening into the developing brain has been neuroimaging proficiencies and animal representations, which can help identify quantitative biomarkers of[ neural] structure state and characterise system differences underlying behaviours." It then include an indication that advances in technology "are opening added possibles in young infants."

The program description goes on to say that artificial neural network, a word of AI, "have demonstrated the viability of modelling network pruning process and their purchases of complex behaviours in much the same way as a developing brain, " while improvements in machine learning, another subset of AI, can now be used to extract "meaningful signals" from the brains of newborns and young children.

These algorithms can then be used to develop "interventions" for young children regarded by other algorithms to be in danger of having underdeveloped brain function.

The document goes on to note the promise of "low-cost portable sensors, wearables and home-based systems" in "providing a new opportunity to assess the influence and dependency of brain development on natural physical and social interactions."

In other statements, this program seeks to use "continuous visual and audio recordings in the home" as well as wearable machines on children to collect millions upon millions of data points. Wellcome Leap describes these wearables as "relatively unassuming, scalable electronic medals that rally visual, auditory and flow data as well as interactive peculiarities( such as turn-taking, speeding and reaction times ). "

Elsewhere in the document there is a call to develop "wearable sensors that assess physiological criteria predictive of brain health( e.g ., electrodermal work, rate of respiration, and heart rate) and wireless wearable EEG or eye-tracking technology" for use in infants and children three and under.

Like other Wellcome Leap planneds, this technology is being developed with the intention of starting it mainstream in medical discipline within the next five to ten years, meaning that this system--although made as a direction to monitor children's brain functioning to improve cognitive outcomes--is a recipe for total surveillance of children and very young children as well as a means for altering their brain functioning as algorithms and Leap's programmers see fit.

1DK has two main program aims. The first is to "develop a fully integrated model and quantitive appraisal tools of network developed as the first 1000 periods[ of life-time ], sufficient to predict EF[ ministerial serve] constitution before a child's first birthday."

Such a pose, the specific characteristics speaks, "should predict contributions of nutrition, the microbiome and the genome" on brain shaping as well as the effects of "sensimotor and social interactions[ or shortfall thereof] on structure snipping processes" and EF outcomes. The second purpose makes it clear that widespread adoption of such neurological-monitoring technologies in children and babes is the endgame for 1DK.

It states that the program plans to "create scalable methods for optimising promotion, prevention, screening and therapeutic involvements to improve EF by at least 20% in 80% of children before age 3. "

True to the eugenicist ties of the Wellcome Trust( to be considered more in-depth in Part 2 ), Wellcome Leap's 1DK notes that "of interest are betterments from underdeveloped EF to normative or from normative to well-developed EF across the population to deliver the most significant impact."

One of the goals of 1DK is thus not treating illnes or addressing a "global health world challenge" but instead experimenting on the cognitive augmentation of children use symbolizes developed by AI algorithms and invasive surveillance-based technology.

Another unsettling aspect of the program is its plan to "develop an in vitro 3D intelligence assembloid that mimics the time formation" of a developing brain that is akin to the poses put forward by monitoring the brain development of babes and children.

Later on, the program description calls this an "in-silico" framework of a child's brain, something of obvious interest to transhumanists who identify such a development as a harbinger of the so-called singularity.

Beyond that, it appears that this in-silico and thus synthetic simulate of the intelligence is planned to be used as the "model" to which infant and children brains are influenced by the "therapeutic interventions" mentioned elsewhere in the program description.

It should be clear how malevolent it is that an organization that brings together the worst "mad scientist" motivations of both the NGO and military-research macrocosms is openly planning to conduct such experimentations on the brains of newborns and toddlers, considering them as datasets and their psyches as something to be "pruned" by machine "intelligence."

Allowing such a program to advance unimpeded without pushback from the public would convey granting a perilous schedule targeting society's youngest and most vulnerable members to potentially advancement to a place where it is difficult to stop.

A "Tissue Time Machine"

The third and second-most recent program to join the Wellcome Leap lineup is called Delta Tissue, abbreviated by the organization as DT. Delta Tissue aims to create a platform that observers changes in human-tissue function and interactions in real term, ostensibly to "explain the status of a disease in each person and better predict how that canker would progress."

Referring to this platform as a "tissue time machine, " Wellcome Leap realise Delta Tissue as being able to predict the onslaught of infection before it appears while also allowing for medical interventions that "are targeted to the individual."

Source: Wellcome Leap, https :// wellcomeleap.org/ delta-tissue /

Well before the COVID era, accuracy medication or prescription "targeted or accommodated to the individual" has been a code phrase for therapies based on patients' genetic data and/ or for cares that vary nucleic acid( e.g ., DNA and RNA) function itself. For example, the US government defines "precision medicine" as "an rising approach for illnes medicine and prevention that makes into account individual variability in genes, environment, and life-style for each person."

Similarly, a 2018 newspaper published in Technology notes that, in oncology, "precision and personalized medicine ... promotes the development of specialized medicines for each specific subtype of cancer, based on the measurement and manipulation of key patient genetic and omic data( transcriptomics, metabolomics, proteomics, etc .). "

Prior to COVID-1 9 and the inoculation roll out, the mRNA vaccine technology used by the DARP-Afunded firms Moderna and Pfizer were marketed as being precision medicine managements and were largely referred to as "gene regimen" in media reports.

They were also promoted heavily as a progressive technique of treating cancer, forming it unsurprising that the Delta Tissue program at Wellcome Leap would use a similar justification to develop a program that aims to offer tailor-make gene rehabilitations to beings before the onslaught of a disease.

This Delta Tissue pulpit works to combine "the latest cell and material profiling technologies with recent advances in machine learning, " that is, AI.

Given Wellcome Leap's connections to the US armed, it is worth noting that the Pentagon and Google, both onetime employers of Wellcome Leap CEO Regina Dugan and COO Ken Gabriel, work collaboratively since last-place September on using AI to predict disease in humans, first focusing on cancer before expanding to COVID-1 9 and every sicknes in between.

The Delta Tissue planned seemed to have pertained aims, as its program description makes clear that the programme eventually aims to use its pulpit for a multitude of cancers and infectious diseases.

The ultimate goal of this Wellcome Leap planned is "to eradicate the obstinately challenging cankers that case so much suffering around the world." It plans to do this through AI algorithms, nonetheless, which are never 100 percentage accurate in their predictive clevernes, and with gene-editing therapies, nearly all of which are novel and have not been well tested.

That latter point is important given that one of the main methods for gene-editing in humen, CRISPR, has been is located within several studies to cause appreciable damage to the DNA, damage that is largely irreparable( realise here, here and here ).

It seems probable that a person placed on such a hi-tech medical treatment path will continue to need a never-ending series of gene-editing treatments and perhaps other invasive hi-tech medications to mitigate and succeed the consequences of unwieldy gene splicing.

Total Surveillance to Treat "Depression"

Wellcome Leap's most recent program, launched this very week, is called "Multi-Channel Psych: Revealing Mechanisms of Anhedonia" and is officially focused on creating "complex, biological" managements for depression.

Source: Wellcome Leap, https :// wellcomeleap.org/ mcpsych /

Those behind Wellcome Leap frame their own problems they aim to tackle with this program as follows 😛 TAGEND

"We understand that synaptic ties serve as the currency movements neural communication, and that strengthening or dampening these connects can facilitate learning new behavioral approaches and ways and means to looking at the world.

Through studies in both animal sits and humans, we have discovered that emotional states are encoded in complex neural network task motifs, and that instantly changing such patterns via brain stimulation can change climate. We also know that disruption of these delicately offset systems can be achieved through neuropsychiatric illness."( emphasis added)

They add that "biologically located treatments" for dimple "are not being coincided to the biology of the human beings they're being used in, " and, thus, managements for dip need to be tailored "to the specific biology" of individual patients. They clearly state that what needs to be addressed in order to make such personal modifications to treatment is to gain "easy access to the biological substrate of depression--i.e. the brain."

Wellcome Leap's program description notes that this effort will focus specifically on anhedonia, which it defines as "an impairment in the effort-based reward system" and as a "key symptom of sadnes and other neuropsychiatric illnesses." Notably, in the fine print of the document, Wellcome Leap commonwealths 😛 TAGEND

"While there are many definitions of anhedonia, we are less interested in the investigation of increased consummatory desire, the general experience of solace, or the inability to experience pleasure. Rather, as per the specific characteristics above, we will prioritize investigations of anhedonia as it relates to disabilities in the effort-based reward system--e.g. shortened motivation to complete assignments and abridged capacity to apply effort to achieve a goal."

In other texts, Wellcome Leap is only interesting to treating the various aspects of depression that interfere with an individual's ability to work , not in improving an individual's quality or pleasure of life.

Leap tones, in discussing its goals, that it seeks to develop patterns for how patients respond to treatments that include "novel or existing behavior modification, psychotherapy, drug, and neurostimulation options" while also capturing an individual's "genome, phenome[ the sum of an individual's phenotypic mannerisms ],[ neural] system connectivity, metabolome[ the sum of an individual's metabolic characters ], microbiome, remuneration processing plasticity heights, " among others.

It eventually aims to predict the relationship between an individual's genome to how "reward processing" runs in the psyche. It implies that the data used to create this simulation should involve the use of wearables, stating that researchers "should seek to leverage high frequency patient-worn or in-home amounts in addition to those obtained in the clinic, hospital or laboratory."

One of the central research areas included in the program sounds to "develop new scalable assessment an instrument for reliable and high-density quantification of humor( both subjectively reported and objectively quantified via biometrics such as voice, facial expression, etc .), sleep, movement, reward system functioning, endeavour/ motivation/ power degrees, social interaction, caloric intake, and HPA axis output in real-world situations."

The HPA( hypothalamic-pituitary-adrenal) axis is mentioned throughout the document, and this is significant as it is both a negative and positive feedback system regulating the mechanisms of stress reactions, exemption, and also fertility in the human body.

The latter is of particular importance given the Wellcome Trust's ties to the UK eugenics move. It is likewise worth noting that some commercially available wearables, such as Amazon's Halo, once quantify mood, sleep, and movement.

The program's columnists go even further than the above in terms of what they wish to monitor in real meter, territory, "We solely encourage the development of non-invasive technology to immediately interrogate human mentality state." Patterns include "a non-invasive spinal tap equivalent, " "behavioral or biomarker examinations of neural plasticity, " and "single-session neural monitoring abilities that outlines a treatment-predictive mentality state."

In other paroles, this Wellcome Leap planned and its scribes seek to develop "non-invasive" and, likely, wearable engineering capable of monitoring an individual's mood, facial expressions, social interactions, attempt and motivating, and potentially even thoughts in order to "directly interrogate human brain state."

To think that such a maneuver would stay only in the realm of research is naive, especially given that WEF luminaries have openly spoken at Davos convenes about how authorities plan to use such technology widely on its own population as a means of pre-emptively targeting would-be dissension and ushering in an era of "digital dictatorships."

The focus on treating only the aspects of depression that interfere with a person's work further suggests that such technology, once developed, would be used to ensure "perfect worker" behavior in manufactures where human craftsmen are rapidly being replaced with AI and machines, intending the rulers can be more selective about which beings continue to be employed and which do not.

Like other Wellcome Leap planneds, if accomplished, the fruits of the Multi-Channel Psych program will likely be used to ensure a population of docile automatons whose shifts and thinkings are heavily surveilled and monitored.

The Last Leap for an Old Agenda

Wellcome Leap is no small endeavor, and its administrators have the funding, force, and connections to make their dreams actuality. The organization's leadership includes the key force behind Silicon Valley's pushing to commercialize transhumanist tech( Regina Dugan ), the "architect" of the MEMS industry( Ken Gabriel ), and the "ruler" of the burgeoning genetic-sequencing industry( Jay Flatley ).

It too benefits from the funding of the world's largest medical-research foundation, the Wellcome Trust, which is also one of the leading actions in mold genetics and biotechnology research as well as health plan globally.

A 1994 Sunday Times investigation into the Trust noticed ... ... that "through[ Wellcome Trust] grants and sponsorships, government agencies, universities, hospitals and scientists are forced all regions of the world. The trust distributes more coin to establishments than even the British government's Medical Research Council." It then memo 😛 TAGEND

"In bureaux on the building's first floor, decisions are contacted that affect lives and health on scales comparable with minor conflicts. In the conference room, high above wall street, and in the gather dorm, in the basement, verdicts in biotechnology and genetics are handed down that will help shape the human race."

Little has changed regarding the Trust's influence since that essay was published. If anything, its influence on study tracks and decisions that will "shape the human race" has only grown. Its ex-DARPA officials, who have invested their vocations advancing transhumanist engineering in both the public and private sectors, have overlapping points with those off Wellcome Leap.

Dugan's and Gabriel's commercial projections in Silicon Valley has indicated that Leap presided over by those who have long sought to advance the same engineering for profit and for surveillance. This drastically debilitates Wellcome Leap's claim to now be pursuing new information and communication technologies to merely improve "global health."

Regina Dugan's Keynote at Facebook F8 2017. Source: YouTube

Indeed, as this report has shown, most of these technologies would be used in a deeply disturbing era of mass surveillance over both the external and internal activities of human beings, including young children and babes, while also creating a new period of remedy based predominantly on gene-editing regimen, the risks of which are considerable and too regularly downplayed by its promoters.

When one understands the insinuate ligament that has long existed between eugenics and transhumanism, Wellcome Leap and its passions see excellent smell. In a recent section written by John Klyczek for Unlimited Hangout, it was noted that the first director general of UNESCO and onetime president of the UK Eugenics Society was Julian Huxley, who coined the call "transhumanism" in his 1957 diary New Bottles for New Wine.

As Klyczek wrote, Huxley argued that "the eugenic goals of biologically engineering human growth should be refined through transhumanist engineerings, which integrate the eugenic methods of genetic engineering with neurotech that consolidates human beings and machines into a new organism."

Earlier, in 1946, Huxley noted in his vision for UNESCO that it was essential that "the eugenic problem is examined with the greatest care and that the public mind is informed of the issues at bet so that much that is now preposterous may at least become thinkable, " an startling testimony to form so soon after the end of World War II.

Thanks in vast duty to the Wellcome Trust and its affect on both policy and medical research over the course of several decades, Huxley's dream of rehabilitating eugenics-infused discipline in the post-World War II era could soon becomes a reality. Unsurprisingly, the Wellcome Trust hosts the archive of the formerly Huxley-led Eugenics Society and still boasts close ties to its successor organization, the Galton Institute.

The over-riding question is: Will we admit ourselves to continue to be controlled into allowing transhumanism and eugenics to be openly prosecuted and normalized, including through initiatives like those of Wellcome Leap that seek to use newborn and toddlers as test subjects to advance their frightening see for humanity?

If well-crafted advertising slogans and media campaigns painting dreams of utopia such as "a world without disease" are all that is needed to convince us to give up our future and our children's future to armed agents, corporate directors, and eugenicists, then there is little left of our humanity to surrender.

Read more: articles.mercola.com